当前位置：
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Factor XIa Inhibitors as New Anticoagulants
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2018-05-18 00:00:00 , DOI: 10.1021/acs.jmedchem.8b00173 Mimi L. Quan 1 , Donald J. P. Pinto 1 , Joanne M. Smallheer 1 , William R. Ewing 1 , Karen A. Rossi 1 , Joseph M. Luettgen 1 , Dietmar A. Seiffert 1 , Ruth R. Wexler 1
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2018-05-18 00:00:00 , DOI: 10.1021/acs.jmedchem.8b00173 Mimi L. Quan 1 , Donald J. P. Pinto 1 , Joanne M. Smallheer 1 , William R. Ewing 1 , Karen A. Rossi 1 , Joseph M. Luettgen 1 , Dietmar A. Seiffert 1 , Ruth R. Wexler 1
Affiliation
|
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.
中文翻译：
因子XIa抑制剂作为新型抗凝剂
随着凝血酶和凝血因子Xa抑制剂被引入口服抗凝剂市场，疗效和安全性都得到了显着改善。早期的临床和临床前数据表明，XIa因子抑制剂可提供更安全的替代方法，并具有扩大的动脉适应症功效。本《观点》概述了目标基本原理，以及发现和开发因子XIa抑制剂作为下一代抗血栓形成剂的细节。
更新日期：2018-05-18
中文翻译：
因子XIa抑制剂作为新型抗凝剂
随着凝血酶和凝血因子Xa抑制剂被引入口服抗凝剂市场，疗效和安全性都得到了显着改善。早期的临床和临床前数据表明，XIa因子抑制剂可提供更安全的替代方法，并具有扩大的动脉适应症功效。本《观点》概述了目标基本原理，以及发现和开发因子XIa抑制剂作为下一代抗血栓形成剂的细节。
京公网安备 11010802027423号